{"id":22127,"date":"2023-02-10T21:54:00","date_gmt":"2023-02-10T13:54:00","guid":{"rendered":"https:\/\/flcube.com\/?p=22127"},"modified":"2025-01-19T21:57:22","modified_gmt":"2025-01-19T13:57:22","slug":"joincares-generic-seretide-accepted-for-nmpa-review","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=22127","title":{"rendered":"Joincare’s Generic Seretide Accepted for NMPA Review"},"content":{"rendered":"\n

China-based Joincare Pharmaceutical Industry Group Co., Ltd (SHA: 600380<\/a>) has announced that the market filing for its generic version of GlaxoSmithKline\u2019s (GSK, NYSE: GSK<\/a>) Seretide (salmeterol, fluticasone) has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant milestone for Joincare, which holds the first-mover position for Seretide in China.<\/p>\n\n\n\n

Seretide: Market and Reimbursement<\/strong>
Seretide was first approved in China in 2001 and is reimbursed as a Category B drug on the National Reimbursement Drug List (NRDL). The generic version, an inhalable powder mist dosage form of the originator, is used as a regular treatment for reversible obstructive airway disease, including asthma and chronic obstructive pulmonary disease (COPD).<\/p>\n\n\n\n

Mechanism of Action<\/strong>
Salmeterol, a long-acting \u03b22 receptor agonist, can permanently relax the bronchus. Fluticasone, a glucocorticoid, is designed to control inflammation and reduce acute attacks. This combination makes Seretide an effective treatment for managing symptoms and improving the quality of life for patients with respiratory conditions.<\/p>\n\n\n\n

Sales and Market Impact<\/strong>
Seretide generated significant sales in 2021, with global sales reaching RMB 12 billion (USD 1.76 billion) and domestic sales in China amounting to RMB 863 million (USD 127.1 million). The acceptance of Joincare’s generic version for review by the NMPA could potentially expand market access and increase treatment options for patients in China.<\/a>-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Joincare Pharmaceutical Industry Group Co., Ltd (SHA: 600380) has announced that the market filing…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[42,31,278,184,676,38,914,965],"class_list":["post-22127","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-first-mover-generic","tag-generic-drugs","tag-glaxosmithkline","tag-gsk","tag-joincare-pharmaceutical","tag-market-approval-filings","tag-nyse-gsk","tag-sha-600380"],"yoast_head":"\nJoincare's Generic Seretide Accepted for NMPA Review - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Joincare Pharmaceutical Industry Group Co., Ltd (SHA: 600380) has announced that the market filing for its generic version of GlaxoSmithKline\u2019s (GSK, NYSE: GSK) Seretide (salmeterol, fluticasone) has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant milestone for Joincare, which holds the first-mover position for Seretide in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=22127\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Joincare's Generic Seretide Accepted for NMPA Review\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=22127\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-10T13:54:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-19T13:57:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22127#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22127\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Joincare’s Generic Seretide Accepted for NMPA Review\",\"datePublished\":\"2023-02-10T13:54:00+00:00\",\"dateModified\":\"2025-01-19T13:57:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22127\"},\"wordCount\":223,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"First-mover generic\",\"Generic drugs\",\"GlaxoSmithKline\",\"GSK\",\"Joincare Pharmaceutical\",\"Market approval filings\",\"NYSE: GSK\",\"SHA: 600380\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22127#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22127\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=22127\",\"name\":\"Joincare's Generic Seretide Accepted for NMPA Review - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-02-10T13:54:00+00:00\",\"dateModified\":\"2025-01-19T13:57:22+00:00\",\"description\":\"China-based Joincare Pharmaceutical Industry Group Co., Ltd (SHA: 600380) has announced that the market filing for its generic version of GlaxoSmithKline\u2019s (GSK, NYSE: GSK) Seretide (salmeterol, fluticasone) has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant milestone for Joincare, which holds the first-mover position for Seretide in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22127#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22127\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22127#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Joincare’s Generic Seretide Accepted for NMPA Review\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Joincare's Generic Seretide Accepted for NMPA Review - Insight, China's Pharmaceutical Industry","description":"China-based Joincare Pharmaceutical Industry Group Co., Ltd (SHA: 600380) has announced that the market filing for its generic version of GlaxoSmithKline\u2019s (GSK, NYSE: GSK) Seretide (salmeterol, fluticasone) has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant milestone for Joincare, which holds the first-mover position for Seretide in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=22127","og_locale":"en_US","og_type":"article","og_title":"Joincare's Generic Seretide Accepted for NMPA Review","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=22127","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-02-10T13:54:00+00:00","article_modified_time":"2025-01-19T13:57:22+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=22127#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=22127"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Joincare’s Generic Seretide Accepted for NMPA Review","datePublished":"2023-02-10T13:54:00+00:00","dateModified":"2025-01-19T13:57:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=22127"},"wordCount":223,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["First-mover generic","Generic drugs","GlaxoSmithKline","GSK","Joincare Pharmaceutical","Market approval filings","NYSE: GSK","SHA: 600380"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=22127#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=22127","url":"https:\/\/flcube.com\/?p=22127","name":"Joincare's Generic Seretide Accepted for NMPA Review - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-02-10T13:54:00+00:00","dateModified":"2025-01-19T13:57:22+00:00","description":"China-based Joincare Pharmaceutical Industry Group Co., Ltd (SHA: 600380) has announced that the market filing for its generic version of GlaxoSmithKline\u2019s (GSK, NYSE: GSK) Seretide (salmeterol, fluticasone) has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant milestone for Joincare, which holds the first-mover position for Seretide in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=22127#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=22127"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=22127#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Joincare’s Generic Seretide Accepted for NMPA Review"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22127"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22127\/revisions"}],"predecessor-version":[{"id":22128,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22127\/revisions\/22128"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22127"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22127"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}